Free Newsletter
GlycoVaxyn banks $22 million in second round
The Swiss vaccine developer GlycoVaxyn has ginned $22 million for its Series B round. Edmond de Rothschild Investment Partners led the round with Index Ventures and Sofinnova Partners joining in.
GlycoVaxyn is a platform company, using new technology to engineer a novel type of conjugate vaccine--glycoconjugates--that can be used to combat bacterial infections. The new money will help push its lead program for intestinal infections into the clinic in 12 months while giving its team more time to hit its milestones on vaccines for Staphylococcus aureus, Group B meningococcal and Group A Streptococcus.
"Under the leadership of CEO Philippe Dro, GlycoVaxyn has established the solid fundamentals required to raise funding in the current economic downturn," noted Michel Greco, chairman of GlycoVaxyn. "The company is well financed for the move into clinical trials."
- check out GlyxoVaxyn's release
Related Articles:
Index eyes biotech plays with $438M fund
Top 20 venture capital deals of 2008
Investors: biotech to rebound, outperform in '09
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: